+

WO1999005172A3 - Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones - Google Patents

Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones Download PDF

Info

Publication number
WO1999005172A3
WO1999005172A3 PCT/CA1998/000715 CA9800715W WO9905172A3 WO 1999005172 A3 WO1999005172 A3 WO 1999005172A3 CA 9800715 W CA9800715 W CA 9800715W WO 9905172 A3 WO9905172 A3 WO 9905172A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
proteins
sequence
hormone
calreticulin
Prior art date
Application number
PCT/CA1998/000715
Other languages
English (en)
Other versions
WO1999005172A2 (fr
Inventor
Shoukat Dedhar
Claus-Jens Walter Doersen
Adam Weislaw Mazur
Original Assignee
Shoukat Dedhar
Doersen Claus Jens Walter
Adam Weislaw Mazur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/377,432 external-priority patent/US5854202A/en
Priority claimed from US08/900,241 external-priority patent/US6518397B1/en
Application filed by Shoukat Dedhar, Doersen Claus Jens Walter, Adam Weislaw Mazur filed Critical Shoukat Dedhar
Priority to JP2000556581A priority Critical patent/JP2002519306A/ja
Priority to KR1020007000808A priority patent/KR20010022235A/ko
Priority to EP98936040A priority patent/EP1001986A2/fr
Priority to CA002298930A priority patent/CA2298930A1/fr
Priority to AU85251/98A priority patent/AU8525198A/en
Publication of WO1999005172A2 publication Critical patent/WO1999005172A2/fr
Publication of WO1999005172A3 publication Critical patent/WO1999005172A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des protéines isolées et purifiées, telles que la calréticuline et les éléments mimétiques et inhibiteurs de la calréticuline, destinées à une nouvelle utilisation permettant de moduler la capacité de réponse aux hormones. Ces protéines sont utiles en thérapie génique et dans la fabrication de produits pharmaceutiques servant à traiter une variété de maladies, dont le cancer, l'ostéoporose et les maladies inflammatoires chroniques. Ces protéines comprennent ou se lient à une séquence d'acides aminés [SEQ ID NO:1] KXFFX11R, dans laquelle X représente G, A ou V, et Y représente soit K, soit R. Cette séquence est présente dans le domaine de liaison de l'ADN et est indispensable à l'activité de liaison à l'ADN d'une variété de récepteurs d'hormones, y compris le récepteur des glucocorticoïdes, le récepteur des minéralocorticoïdes, le récepteur des androgènes, le récepteur de la progestérone, le récepteur des oestrogènes, le récepteur de l'acide rétinoïque, le récepteur des hormones thyroïdiennes et le récepteur de la vitamine D. Les protéines qui se fixent à cette séquence peuvent inhiber la transcription génique induite par un récepteur d'hormone. Les protéines qui comprennent cette séquence peuvent favoriser la transcription génique induite par un récepteur d'hormone. Cette invention concerne également les molécules d'ADN isolées pour ces protéines, des méthodes pour traiter des maladies à l'aide de ces protéines, des peptides synthétiques et leurs éléments mimétiques, ainsi que des nécessaires comprenant ces protéines, ces peptides synthétiques ou leurs éléments mimétiques.
PCT/CA1998/000715 1995-01-24 1998-07-24 Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones WO1999005172A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000556581A JP2002519306A (ja) 1997-07-24 1998-07-24 ホルモン応答性を調節するための製薬
KR1020007000808A KR20010022235A (ko) 1997-07-24 1998-07-24 호르몬 반응성을 조절하기 위한 약제
EP98936040A EP1001986A2 (fr) 1997-07-24 1998-07-24 Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones
CA002298930A CA2298930A1 (fr) 1997-07-24 1998-07-24 Medicaments pour la modulation de receptivite d'hormone
AU85251/98A AU8525198A (en) 1997-07-24 1998-07-24 Pharmaceuticals for modulating hormone responsiveness

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/377,432 US5854202A (en) 1995-01-24 1995-01-24 Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
US08/900,241 US6518397B1 (en) 1997-07-24 1997-07-24 Pharmaceuticals for modulating hormone responsiveness
US08/900,241 1997-07-24

Publications (2)

Publication Number Publication Date
WO1999005172A2 WO1999005172A2 (fr) 1999-02-04
WO1999005172A3 true WO1999005172A3 (fr) 1999-04-15

Family

ID=27007809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1998/000715 WO1999005172A2 (fr) 1995-01-24 1998-07-24 Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones

Country Status (1)

Country Link
WO (1) WO1999005172A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220024944A1 (en) * 2018-10-23 2022-01-27 Myelopro Diagnostics And Research Gmbh Compounds targeting mutant calreticulin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014098A1 (fr) * 1992-01-10 1993-07-22 Sloan-Kettering Institute For Cancer Research Antigene reconnu chez les patients avec le syndrome myasthenique de lambert. eaton (lems) associe a l'anticorps, adn codant celui-ci et son utilisation
CA2140814A1 (fr) * 1995-01-23 1996-07-24 Shoukat Dedhar Utilisation de calreticuline pour la modulation de la receptivite hormonale et nouveaux produits pharmaceutiques servant au traitement du cancer, de l'osteoporose et des maladies inflammatoires chroniques
WO1996023001A1 (fr) * 1995-01-24 1996-08-01 Shoukat Dedhar Nouveaux composes pharmaceutiques pour moduler la capacite de reponse aux hormones

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014098A1 (fr) * 1992-01-10 1993-07-22 Sloan-Kettering Institute For Cancer Research Antigene reconnu chez les patients avec le syndrome myasthenique de lambert. eaton (lems) associe a l'anticorps, adn codant celui-ci et son utilisation
CA2140814A1 (fr) * 1995-01-23 1996-07-24 Shoukat Dedhar Utilisation de calreticuline pour la modulation de la receptivite hormonale et nouveaux produits pharmaceutiques servant au traitement du cancer, de l'osteoporose et des maladies inflammatoires chroniques
WO1996023001A1 (fr) * 1995-01-24 1996-08-01 Shoukat Dedhar Nouveaux composes pharmaceutiques pour moduler la capacite de reponse aux hormones

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COPPOLINO M G ET AL: "CALRETICULIN IS ESSENTIAL FOR INTEGRIN-MEDIATED CALCIUM SIGNALLING AND CELL ADHESION", NATURE, vol. 386, 24 April 1997 (1997-04-24), pages 843 - 847, XP002072201 *
Y. CHOI ET AL.: "Tissue-specific and developmental regulation of a gene encoding a low-molecular weight sulfur-rich protein in soybean seeds", MOL. GEN. GENET, vol. 246, 1995, pages 266 - 268, XP002092536 *

Also Published As

Publication number Publication date
WO1999005172A2 (fr) 1999-02-04

Similar Documents

Publication Publication Date Title
Dedhar et al. Inhibition of nuclear hormone receptor activity by calreticulin
Sadowski et al. Cell-free activation of a DNA-binding protein by epidermal growth factor
Wilkinson et al. Stimulation of ATP-dependent proteolysis requires ubiquitin with the COOH-terminal sequence Arg-Gly-Gly.
Cheng et al. Regulation of DNA replication in vitro by the transcriptional activation domain of GAL4-VP16.
Jain et al. Nuclear factor of activated T cells contains Fos and Jun
Horikoshi et al. Mechanism of action of a yeast activator: direct effect of GAL4 derivatives on mammalian TFIID-promoter interactions
Dash et al. cAMP response element-binding protein is activated by Ca2+/calmodulin-as well as cAMP-dependent protein kinase.
Liu et al. Steroidogenic factor 1 (SF-1) and SP1 are required for regulation of bovine CYP11A gene expression in bovine luteal cells and adrenal Y1 cells
Day et al. A protein kinase inhibitor gene reduces both basal and multihormone-stimulated prolactin gene transcription
Scearce et al. RNR-1, a nuclear receptor in the NGFI-B/Nur77 family that is rapidly induced in regenerating liver.
Bugler et al. RNA binding fragments from nucleolin contain the ribonucleoprotein consensus sequence.
Rishi et al. Estradiol regulation of the human retinoic acid receptor α gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs
Dunn et al. The insulator binding protein CTCF associates with the nuclear matrix
Gordon et al. Type V collagen and Bowman's membrane. Quantitation of mRNA in corneal epithelium and stroma.
AU779461C (en) Osteoprotegerin binding proteins and receptors
Ristiniemi et al. Histone H1 binds to the putative nuclear factor I recognition sequence in the mouse α2 (I) collagen promoter
ATE270303T1 (de) Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper
Kubota et al. Signaling site of laminin with mitogenic activity.
Hale et al. Carboxyl-terminal proteolytic processing of matrix Gla protein.
Kagawa et al. A cAMP-regulatory sequence (CRS1) of CYP17 is a cellular target for the homeodomain protein Pbx1.
Banerjee et al. Distinct colchicine binding kinetics of bovine brain tubulin lacking the type III isotype of beta-tubulin
AU4422893A (en) Monoclonal antibody against protein C
Maloy et al. Amino acid sequence of the biotinyl subunit from transcarboxylase.
Pande et al. Primary structure of a glycosylated DNA-binding domain in human plasma fibronectin.
WO1999005172A3 (fr) Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2298930

Country of ref document: CA

Ref country code: CA

Ref document number: 2298930

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020007000808

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 85251/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998936040

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09463629

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998936040

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007000808

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998936040

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007000808

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载